หน้าแรก
ค้นหา
Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC
KEYNOTE-564 study
Dr. Zhang on Challenges With Vaccines in Renal Cell Carcinoma
Tian Zhang, MD, shares thoughts on the PDIGREE trial in metastatic, untreated RCC
A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma
Dr. Zhang on the ARCHES Trial in Prostate Cancer
Considerations for Using Adjuvant Therapy in mRCC
Emerging role of adjuvant immunotherapy in oncology
Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting
Clinical Trials of Post-Progression Therapy for mRCC
Deciding on the optimal 1L treatment for patients with advanced RCC
Phase 3 CheckMate - 214
Therapeutic algorithm for Renal Cell Carcinoma (RCC)
Dr. George on Critical Clinical Trials in Kidney Cancer
Novel Therapeutic Strategies to Individualize Patient Care in RCC: Expert-Led Clinical Consults
Dr. Sznol on Patient Selection for Combination Therapy in mRCC
New Developments in Adjuvant Therapy for Renal Cell Carcinoma Scott S. Tykodi, M.D., Ph.D.
Kidney cancer research at ESMO 2021
Potential prognostic markers in sarcomatoid and rhabdoid RCC
Rethinking the Care of Renal Cell Carcinoma
